Device Trial Radar · NCT06636175
64Cu-LLP2A for Imaging Hematologic Malignancies
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
21
Actual
Start
Mar 20, 2025
Primary completion
Aug 28, 2026
Study completion Aug 28, 2026
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Oct 10, 2024
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (MM), low-grade lymphoma, or MM and lymphoma patients who are status post bone marrow transplant (BMT) with negative imaging and suspected recurrence.
Conditions
- Multiple Myeloma
- Low-Grade Lymphoma
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Lymphoplasmacytic Lymphoma
- Small Lymphocytic Lymphoma
- Chronic Lymphocytic Leukemia
Interventions
64Cu-LLP2ADrug
64Cu-LLP2A, will be manufactured following batch production record at the cyclotron GMP facility (Washington University School of Medicine GMP radiochemistry/cyclotron facility)
PET/CTDevice
The results of 64Cu-LLP2A-PET/CT will not be provided to the patient or the treating oncologist/surgeon unless, in the judgment of the principal investigator, the images demonstrate an unsuspected abnormality that may warrant further evaluation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Organ dosimetry of participantsTime frame: Through completion of PET/CT scans (estimated to be up to 2 days)
- Safety and tolerability of new formulation of 64Cu-LLP2A as measured by number of participants with adverse eventsTime frame: From beginning of administration of 64Cu-LLPA2A through last phone call assessment (up to 7 days total)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Washington University School of Medicine
St Louis, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.